Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis

DiaTech is a private company performing patient specific cancer chemosensitivity testing for patients and physicians. DiaTech Oncology is doing this clinical study to see if an experimental new technology called the microculture kinetic (MiCK) assay will predict treatment outcome and can help to direct the chemotherapy of cancer subjects. This study is focused on subjects diagnosed with breast, ovarian, lung, and colon malignancies and low-grade lymphomas. Study Objectives: * To evaluate the ability of the MiCK assay to predict the outcome of chemotherapy of cancer patients. * To evaluate the ability of the MiCK assay to guide chemotherapy of cancer patients.